Shantenu Jha

Shantenu Jha

Auto-generated profile, based on publicly available information

Shantenu Jha

Rutgers University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
ACAustin Clyde
Austin Clyde
SGStephanie Galanie
Stephanie Galanie
DKDaniel W. Kneller
Daniel W. Kneller
HMHeng Ma
Heng Ma
YBYadu Babuji
Yadu Babuji
RSRick L. Stevens
Rick L. Stevens
Despite the recent availability of vaccines against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the search for inhibitory therapeutic agents has assumed importance especially in the context of emerging new viral variants. In this paper, we describe the discovery of a novel noncovalent small-molecule inhibitor, MCULE-5948770040, that binds to and inhibits the SARS-Cov-2 main protease (Mpro) by employing a scalable high-throughput virtual screening (HTVS) framework and a targeted compound library of over 6.5 million molecules that could be readily ordered and purchased. Our HTVS framework leverages the U.S. supercomputing infrastructure achieving nearly 91% resource utilization and nearly 126 million docking calculations per hour. Downstream biochemical assays validate this Mpro inhibitor with an inhibition constant (Ki) of 2.9 μM (95% CI 2.2, 4.0). Furthermore, using room-temperature X-ray crystallography, we show that MCULE-5948770040 binds to a cleft in the primary binding site of Mpro forming stable hydrogen bond and hydrophobic interactions. We then used multiple μs-time scale molecular dynamics (MD) simulations and machine learning (ML) techniques to elucidate how the bound ligand alters the conformational states accessed by Mpro, involving motions both proximal and distal to the binding site. Together, our results demonstrate how MCULE-5948770040 inhibits Mpro and offers a springboard for further therapeutic design.

17 April 2018 in ACM Computing Surveys
Verified
Journal Article
Open access
PDF file
MTMatteo Turilli
Matteo Turilli
MSMark Santcroos
Mark Santcroos
SJShantenu Jha
Shantenu Jha
Pilot-Job systems play an important role in supporting distributed scientific computing. They are used to execute millions of jobs on several cyberinfrastructures worldwide, consuming billions of CPU hours a year. With the increasing importance of task-level parallelism in high-performance computing, Pilot-Job systems are also witnessing an adoption beyond traditional domains. Notwithstanding the growing impact on scientific research, there is no agreement on a definition of Pilot-Job system and no clear understanding of the underlying abstraction and paradigm. Pilot-Job implementations have proliferated with no shared best practices or open interfaces and little interoperability. Ultimately, this is hindering the realization of the full impact of Pilot-Jobs by limiting their robustness, portability, and maintainability. This article offers a comprehensive analysis of Pilot-Job systems critically assessing their motivations, evolution, properties, and implementation. The three main contributions of this article are as follows: (1) an analysis of the motivations and evolution of Pilot-Job systems; (2) an outline of the Pilot abstraction, its distinguishing logical components and functionalities, its terminology, and its architecture pattern; and (3) the description of core and auxiliary properties of Pilot-Jobs systems and the analysis of six exemplar Pilot-Job implementations. Together, these contributions illustrate the Pilot paradigm, its generality, and how it helps to address some challenges in distributed scientific computing.

9 August 2024 in Computer
Verified
Journal Article
Closed access
RSRafael Ferreira Da Silva
Rafael Ferreira Da Silva
RBRosa M. Badia
Rosa M. Badia
DBDeborah Bard
Deborah Bard
IFIan Foster
Ian Foster
SJShantenu Jha
Shantenu Jha
FSFrédéric Suter
Frédéric Suter
We address the increasing complexity of scientific workflows in the context of high-performance computing (HPC) and their associated need for robust, adaptable, and flexible computational support systems. We explore five key trends as well as future challenges and opportunities for scientific workflows and HPC technologies.

1 October 2018 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
PKPeter M Kasson
Peter M Kasson
SJShantenu Jha
Shantenu Jha

9 August 2021
Verified
Conference Paper
Open access
ASAymen Al Saadi
Aymen Al Saadi
DADario Alfe
Dario Alfe
YBYadu Babuji
Yadu Babuji
ABAgastya Bhati
Agastya Bhati
BBBen Blaiszik
Ben Blaiszik
JYJunqi Yin
Junqi Yin
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2–3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silico methodologies need to be improved both to select better lead compounds, so as to improve the efficiency of later stages in the drug discovery protocol, and to identify those lead compounds more quickly. No known methodological approach can deliver this combination of higher quality and speed. Here, we describe an Integrated Modeling PipEline for COVID Cure by Assessing Better LEads (IMPECCABLE) that employs multiple methodological innovations to overcome this fundamental limitation. We also describe the computational framework that we have developed to support these innovations at scale, and characterize the performance of this framework in terms of throughput, peak performance, and scientific results. We show that individual workflow components deliver 100 × to 1000 × improvement over traditional methods, and that the integration of methods, supported by scalable infrastructure, speeds up drug discovery by orders of magnitudes. IMPECCABLE has screened ∼ 1011 ligands and has been used to discover a promising drug candidate. These capabilities have been used by the US DOE National Virtual Biotechnology Laboratory and the EU Centre of Excellence in Computational Biomedicine.

1 May 2022
Verified
Conference Paper
Open access
ABAlexander Brace
Alexander Brace
IYIgor Yakushin
Igor Yakushin
HMHeng Ma
Heng Ma
ATAnda Trifan
Anda Trifan
TMTodd Munson
Todd Munson
SJShantenu Jha
Shantenu Jha
Machine learning (ML)-based steering can improve the performance of ensemble-based simulations by allowing for online selection of more scientifically meaningful computations. We present DeepDriveMD, a framework for ML-driven steering of scientific simulations that we have used to achieve orders-of-magnitude improvements in molecular dynamics (MD) performance via effective coupling of ML and HPC on large parallel computers. We discuss the design of DeepDriveMD and characterize its performance. We demonstrate that DeepDriveMD can achieve between 100-1000× acceleration for protein folding simulations relative to other methods, as measured by the amount of simulated time performed, while covering the same conformational landscape as quantified by the states sampled during a simulation. Experiments are performed on leadership-class platforms on up to 1020 nodes. The results establish DeepDriveMD as a high-performance framework for ML-driven HPC simulation scenarios, that supports diverse MD simulation and ML back-ends, and which enables new scientific insights by improving the length and time scales accessible with current computing capacity.